Trial Profile
Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Envafolimab (Primary) ; Gemcitabine; Oxaliplatin
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms KN035-BTC
- Sponsors 3D Medicines; Alphamab Oncology
- 29 Aug 2022 According to a TRACON Pharmaceuticals media release, this study is sponsored by Tracon's corporate partners, Alphamab Oncology and 3D Medicines.
- 06 Mar 2022 Status changed from active, no longer recruiting to recruiting.
- 02 Mar 2022 Planned End Date changed from 30 Jun 2022 to 30 Jul 2024.